Amphotericin B Combination Therapy for Lower-Toxicity Cryptococcus Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cryptococcal meningitis, primarily using amphotericin B, suffer from adverse reactions and limited efficacy due to drug-resistant fungal strains, necessitating improved antifungal agents with enhanced fungicidal activity and reduced toxicity.
Innovation Solution
Combining an inositol phosphorylceramide synthase inhibitor, such as aureobasidin A, with amphotericin B enhances fungicidal activity, prolongs amphotericin B's pharmacological action, and reduces adverse effects by targeting the fungal plasma membrane component inositol phosphorylceramide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amphotericin B is used at high dose to improve fungicidal activity, then therapeutic efficacy is improved, but hepatotoxicity and nephrotoxicity increase
Solution Approach 1:
The patent combines inositol phosphorylceramide synthase inhibitor (such as aureobasidin A) with amphotericin B to create a synergistic antifungal regimen. This combination allows the use of lower doses of amphotericin B while maintaining or enhancing therapeutic efficacy, thereby reducing hepatotoxicity and nephrotoxicity associated with high-dose monotherapy
2Reliability
If amphotericin B is used alone to treat cryptococcal meningitis, then fungicidal activity is achieved, but drug-resistant fungal strains reduce treatment effectiveness
Solution Approach 1:
The patent employs a composite therapeutic approach by combining two antifungal agents with different mechanisms of action: inositol phosphorylceramide synthase inhibitor (targeting cell membrane synthesis) and amphotericin B (targeting ergosterol-containing membranes). This composite regimen overcomes drug resistance by attacking the fungus through multiple pathways simultaneously
3Ease of manufacture
If inositol phosphorylceramide synthase inhibitor is used alone, then it targets fungal plasma membrane component, but fungicidal activity is insufficient
Solution Approach 1:
The patent combines inositol phosphorylceramide synthase inhibitor with amphotericin B to achieve synergistic fungicidal activity. The inhibitor provides targeted action against fungal plasma membrane synthesis, while amphotericin B provides broad-spectrum fungicidal activity, together creating a regimen with both high specificity and high efficacy
4Object-affected harmful factors
If low-dose amphotericin B is used to reduce adverse reactions, then hepatotoxicity and nephrotoxicity are reduced, but fungicidal activity is insufficient
Solution Approach 1:
The patent combines inositol phosphorylceramide synthase inhibitor with low-dose amphotericin B to achieve synergistic fungicidal activity. This combination allows the use of lower doses of amphotericin B (reducing adverse reactions) while maintaining or enhancing fungicidal activity through the additive and synergistic effects of the two agents
Data Source
AI summary
Provided are a combination of an inositol phosphorylceramide synthase inhibitor and amphotericin B and use thereof. The use includes preparing a pharmaceutical composition, which includes an inositol phosphorylceramide synthetase inhibitor and amphotericin B or a salt thereof. Inositol phosphorylceramide is an important and conserved component of fungal plasma membranes. In the pharmaceutical composition according to an embodiment of the present disclosure, due to the presence of the inositol phosphorylceramide synthase inhibitor, the interaction between the inositol phosphorylceramide synthase inhibitor and amphotericin B not only enhances the inhibitory ability of the inositol phosphorylceramide synthase inhibitor on the synthesis of inositol phosphorylceramide in Cryptococcus, but also effectively reduces the dosage of amphotericin B and prolongs the half-life of amphotericin B, facilitating to reduce the adverse reactions of amphotericin B. The pharmaceutical composition exhibits superior fungicidal effect and safety compared to the currently used clinical combination of 5-fluorocytosine and amphotericin B.